Cingulate

Cingulate P/B

The P/B (Price-to-Book Ratio) of Cingulate (CING) as of Nov 11, 2026 is 32.74. In the previous year, P/B (Price-to-Book Ratio) was 11.02 — a change of 197.16% (higher).

P/B

32.74

YoY

197.16%

Last updated:

P/B (Price-to-Book Ratio) of Cingulate is 2025 32.74 . P/B (Price-to-Book Ratio) of Cingulate was 2024 11.02 . It decreases by 197.16% higher compared to the previous year.

The Cingulate P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
133.39 USD
Jan 1, 2020
63.56 USD
Jan 1, 2021
3.94 USD
Jan 1, 2022
21.16 USD
Jan 1, 2023
-11.96 USD
Jan 1, 2024
11.02 USD
Jan 1, 2025
32.74 USD
The Cingulate P/B history
YEARP/BYoY
32.74+197.16%
11.02-192.14%
-11.96-156.51%
21.16+436.92%
3.94-93.80%
63.56-52.35%
133.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

P/B (Price-to-Book Ratio) of Cingulate is 32.74 in 2025.

P/B (Price-to-Book Ratio) of Cingulate changed from 11.02 to 32.74, representing a 197.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Cingulate since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cingulate

All Key Metrics — Cingulate